Equities research analysts predict that Arsanis Inc (NASDAQ:ASNS) will announce earnings of ($0.49) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Arsanis’ earnings. The business is expected to announce its next quarterly earnings report on Monday, November 12th.
On average, analysts expect that Arsanis will report full year earnings of ($2.46) per share for the current year. For the next financial year, analysts anticipate that the firm will post earnings of ($1.51) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Arsanis.
Arsanis (NASDAQ:ASNS) last posted its quarterly earnings results on Monday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.03).
A number of research firms have recently issued reports on ASNS. Zacks Investment Research lowered shares of Arsanis from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. Piper Jaffray Companies reduced their price target on shares of Arsanis to $2.50 and set a “neutral” rating for the company in a research report on Monday, August 13th. Citigroup lowered shares of Arsanis from a “buy” rating to a “neutral” rating in a research report on Monday, July 9th. Cowen lowered shares of Arsanis from an “outperform” rating to a “market perform” rating in a research report on Monday, July 2nd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 price objective on shares of Arsanis in a research report on Thursday, June 28th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Arsanis presently has a consensus rating of “Hold” and a consensus target price of $14.88.
Shares of NASDAQ ASNS traded down $0.07 during mid-day trading on Thursday, reaching $1.42. The company had a trading volume of 144,600 shares, compared to its average volume of 127,585. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.54 and a quick ratio of 5.54. The firm has a market capitalization of $21.47 million and a price-to-earnings ratio of -0.09. Arsanis has a 12-month low of $1.39 and a 12-month high of $28.69.
A number of institutional investors and hedge funds have recently modified their holdings of ASNS. Schwab Charles Investment Management Inc. bought a new position in Arsanis during the first quarter valued at approximately $200,000. Northern Trust Corp bought a new position in Arsanis during the first quarter valued at approximately $735,000. BlackRock Inc. bought a new position in Arsanis during the first quarter valued at approximately $4,029,000. JPMorgan Chase & Co. raised its position in Arsanis by 6.4% during the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock valued at $5,663,000 after acquiring an additional 14,819 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in Arsanis during the first quarter valued at approximately $114,000. 68.70% of the stock is currently owned by hedge funds and other institutional investors.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.